Congenital Anomalies Treatment Market Insights, Size & Growth Forecast To 2031

Table of Content Download Free Sample Now

Report ID: 2702 | Published On: Feb 04, 2022

Preview Analysis

Request Insights

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.

In The News

December 20, 2021: Merck KGaA announced the acquisition of Chord Therapeutics to expand its neuro-inflammatory pipeline, to develop cladribine drug.
December 01, 2020: Fresenius Kabi launched a new Icatibant injection to treat acute attacks of hereditary angioedema in adults. Icatibant injection is an FDA-approved, cost-effective and quick-relief alternative to treat attacks of hereditary angioedema (HAE).

Key Questions Answered in the Report

1) What are the major factors driving the growth of the congenital anomalies treatment market?

Ans: Increasing prevalence of congenital anomalies is estimated to boost the market growth.

2) What would be the CAGR of congenital anomalies treatment market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~10% over the forecast period, i.e., 2022 – 2031.

5) Who are the major players dominating the congenital anomalies treatment market?

Ans: The major players in the market are GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Merck KGaA, Novartis International AG, Ipsen Pharma, Fresenius Kabi USA, and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the congenital anomalies treatment market?

Ans: The market is segmented by type, treatment, end-user, and by region.

8) Which segment captures the largest market size in end-user segment in the congenital anomalies treatment market?

Ans: The hospitals segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.

8) What are the challenges affecting the market growth?

Ans: High cost of treatment and diagnosis are estimated to hamper the market growth.

8) Which region will provide more business opportunities for growth of the congenital anomalies treatment market in future?

Ans: The North America region is anticipated to provide more business opportunities over the forecast period owing to the high prevalence of various kinds of congenital abnormalities amongst the population.

Congenital Anomalies Treatment Market